Why Caris Life Sciences, Inc.’s (CAI) Stock Is Up 6.95%
As of Friday, August 07, Caris Life Sciences, Inc.’s CAI share price has surged by 6.95%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Commentary & Analysis
Why Caris Life Sciences, Inc.’s (CAI) Stock Is Up 14.85%
As of Thursday, August 06, Caris Life Sciences, Inc.’s CAI share price has surged by 14.85%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Caris Life Sciences, Inc.’s (CAI) Stock Is Up 16.57%
As of Thursday, August 06, Caris Life Sciences, Inc.’s CAI share price has surged by 16.57%, which has investors questioning if this is right time to sell.Tudor Pop
What You Need to Know About Caris Life Sciences, Inc.'s Q3 Earnings
Caris Life Sciences, Inc.'s fiscal Q3 earnings report was released on Wednesday, August 05. Let's dive in to see if (CAI) missed or beat analyst's expectations.Tudor Pop
Is Caris Life Sciences, Inc. (CAI) Overvalued?
We dive into why Caris Life Sciences, Inc. (CAI) could be considered overvalued on 2026-07-30, based on AAII’s Value Score and Grade.Michael Rose
Financial Summary
| Share Statistics | CAI | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $6,425.9 | $271.6 | 71% |
|
| Shares Out (Mil) | 282.6 | 51.2 | 82% |
|
| Institutional Ownership | 48.0% | 92.3% | 22% |
|
| Float (Mil) | 103.1 | 39.8 | 62% |
|
| Beta | na | 0.93 | na |
|
| Avg Daily Volume (000s) | 5,790 | 489 | 93% |
|
| Price Change (52-week) |
(21.5%) | 57.7% | 28% |
|
| Growth | CAI | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 10 | |
| Current EPS | $0.030 | $0.149 | $0.368 | |
| Month Ago EPS | $0.044 | $0.133 | $0.366 | |
| # Rev Up | 0 | 2 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | $0.043 | $0.140 | $0.367 | |
| Year/Year Chg | (1,600%) | (104.6%) | (116.0%) | |
| Financials | CAI | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $907 | $37 | 49% |
|
| Net Income (TTM) (Mil) | $34 | ($44) | 53% |
|
| EPS (TTM) | ($1.797) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | $147 | ($31) | 56% |
|
| Net Cash Flow (TTM) (Mil) | $788 | $3 | 94% |
|
| Long-Term Debt (Q1) (Mil) | $425 | $4 | 57% |
|
| Enterprise Value (Q1) (Mil) | $4,660 | $190 | 62% |
|
| Valuation | CAI | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.83 | 2.82 | 91% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | CAI | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 69.8% | 63.8% | 81% |
|
| Net Margin | 10.6% | (70.6%) | 64% |
|
| ROA | 4.7% | (49.3%) | 70% |
|
| ROE | (3.4%) | (58.1%) | 32% |
|
| Liabilities to Assets | 48.9% | 30.5% | 41% |
|
| F-Score | 5 | 3 | 50% |
|
Passing Stock Screens
As of 8/7/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Kirkpatrick Growth Screen
Factors: Momentum, Growth
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 14.2% |
| +/- S&P 500: | +6.7 |
